24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      High-flow nasal cannula ventilation therapy for obstructive sleep apnea in ischemic stroke patients requiring nasogastric tube feeding: a preliminary study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Obstructive sleep apnea (OSA) is associated with increasing risk of recurrent stroke and mortality. Nasogastric tubes used by dysphagic stroke patients may interfere with nasal continuous positive airway pressure (CPAP) due to air leakage. This study was evaluated the effects and short-term tolerability of high-flow nasal cannula (HFNC) therapy for OSA in stroke patients with nasogastric intubation. The HFNC titration study was performed in post-acute ischemic stroke patients with nasogastric intubation and OSA. Then, participants were treated with HFNC therapy in the ward for one week. Eleven participants (eight males) who were all elderly with a median age of 72 (IQR 67–82) years and a body mass index of 23.5 (IQR 22.0–26.6) completed the titration study. The HFNC therapy at a flow rate up to 50~60 L/min significantly decreased the apnea-hypopnea index from 52.0 events/h (IQR 29.9–61.9) to 26.5 events/h (IQR 3.3–34.6) and the total arousal index from 34.6 (IQR 18.6–42.3) to 15.0 (IQR 10.3–25.4). The oxygen desaturation index was also significantly decreased from 53.0 events/h (IQR 37.0–72.8) to 16.2 events/h (IQR 0.8–20.1), accompanied by a significant improvement in the minimum SpO 2 level. Finally, only three participants tolerated flow rates of 50~60 L/minute in one-week treatment period. Conclusively, HFNC therapy at therapeutic flow rate is effective at reducing the OSA severity in post-acute ischemic stroke patients with nasogastric intubation. Owing to the suboptimal acceptance, HFNC might be a temporary treatment option, and CPAP therapy is suggested after the nasogastric tube is removed.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea.

          Positive airway pressure (PAP) devices are used to treat patients with sleep related breathing disorders (SRBDs), including obstructive sleep apnea (OSA). After a patient is diagnosed with OSA, the current standard of practice involves performing attended polysomnography (PSG), during which positive airway pressure is adjusted throughout the recording period to determine the optimal pressure for maintaining upper airway patency. Continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BPAP) represent the two forms of PAP that are manually titrated during PSG to determine the single fixed pressure of CPAP or the fixed inspiratory and expiratory positive airway pressures (IPAP and EPAP, respectively) of BPAP for subsequent nightly usage. A PAP Titration Task Force of the American Academy of Sleep Medicine reviewed the available literature. Based on this review, the Task Force developed these recommendations for conducting CPAP and BPAP titrations. Major recommendations are as follows: (1) All potential PAP titration candidates should receive adequate PAP education, hands-on demonstration, careful mask fitting, and acclimatization prior to titration. (2) CPAP (IPAP and/or EPAP for patients on BPAP) should be increased until the following obstructive respiratory events are eliminated (no specific order) or the recommended maximum CPAP (IPAP for patients on BPAP) is reached: apneas, hypopneas, respiratory effort-related arousals (RERAs), and snoring. (3) The recommended minimum starting CPAP should be 4 cm H2O for pediatric and adult patients, and the recommended minimum starting IPAP and EPAP should be 8 cm H2O and 4 cm H2O, respectively, for pediatric and adult patients on BPAP. (4) The recommended maximum CPAP should be 15 cm H2O (or recommended maximum IPAP of 20 cm H2O if on BPAP) for patients or = 12 years. (5) The recommended minimum IPAP-EPAP differential is 4 cm H2O and the recommended maximum IPAP-EPAP differential is 10 cm H2O (6) CPAP (IPAP and/or EPAP for patients on BPAP depending on the type of event) should be increased by at least 1 cm H2O with an interval no shorter than 5 min, with the goal of eliminating obstructive respiratory events. (7) CPAP (IPAP and EPAP for patients on BPAP) should be increased from any CPAP (or IPAP) level if at least 1 obstructive apnea is observed for patients or = 12 years. (8) CPAP (IPAP for patients on BPAP) should be increased from any CPAP (or IPAP) level if at least 1 hypopnea is observed for patients or = 12 years. (9) CPAP (IPAP for patients on BPAP) should be increased from any CPAP (or IPAP) level if at least 3 RERAs are observed for patients or = 12 years. (10) CPAP (IPAP for patients on BPAP) may be increased from any CPAP (or IPAP) level if at least 1 min of loud or unambiguous snoring is observed for patients or = 12 years. (11) The titration algorithm for split-night CPAP or BPAP titration studies should be identical to that of full-night CPAP or BPAP titration studies, respectively. (12) If the patient is uncomfortable or intolerant of high pressures on CPAP, the patient may be tried on BPAP. If there are continued obstructive respiratory events at 15 cm H2O of CPAP during the titration study, the patient may be switched to BPAP. (13) The pressure of CPAP or BPAP selected for patient use following the titration study should reflect control of the patient's obstructive respiration by a low (preferably 3 hr).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            High-flow nasal cannula oxygen therapy in adults

            High-flow nasal cannula (HFNC) oxygen therapy comprises an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal cannula. It delivers adequately heated and humidified medical gas at up to 60 L/min of flow and is considered to have a number of physiological effects: reduction of anatomical dead space, PEEP effect, constant fraction of inspired oxygen, and good humidification. While there have been no big randomized clinical trials, it has been gaining attention as an innovative respiratory support for critically ill patients. Most of the available data has been published in the neonatal field. Evidence with critically ill adults are poor; however, physicians apply it to a variety of patients with diverse underlying diseases: hypoxemic respiratory failure, acute exacerbation of chronic obstructive pulmonary disease, post-extubation, pre-intubation oxygenation, sleep apnea, acute heart failure, patients with do-not-intubate order, and so on. Many published reports suggest that HFNC decreases breathing frequency and work of breathing and reduces needs of escalation of respiratory support in patients with diverse underlying diseases. Some important issues remain to be resolved, such as its indication, timing of starting and stopping HFNC, and escalating treatment. Despite these issues, HFNC oxygen therapy is an innovative and effective modality for the early treatment of adults with respiratory failure with diverse underlying diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Obstructive sleep apnea and cardiovascular risk: meta-analysis of prospective cohort studies.

              Previous studies suggest obstructive sleep apnea (OSA) may increase cardiovascular risk, but the results are inconclusive due to various limitations. We aimed to systematically evaluate the effect of OSA on the incidence of cardiovascular events by a meta-analysis of prospective cohort studies. We searched multiple electronic databases for studies that examined the prospective relationship between OSA and incidence of coronary heart disease (CHD), stroke, or total cardiovascular diseases (CVD) among adults. Either fixed- or random-effects models were used to calculate the pooled risk estimates. Sensitivity analysis was conducted to examine the robustness of pooled outcomes. Of 17 studies included, 9 reported results on total CVD, 7 reported on fatal or non-fatal CHD, and 10 reported on fatal or non-fatal stroke. The pooled relative risks (95% confidence interval) for individuals with moderate-severe OSA compared with the reference group were 2.48 (1.98-3.10) for total CVD, 1.37 (0.95-1.98) for CHD, and 2.02 (1.40-2.90) for stroke. These results did not materially change in the sensitivity analyses according to various inclusion criteria. In conclusion, findings from this meta-analysis supported that moderate-severe OSA significantly increased cardiovascular risk, in particular stroke risk. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                jongyau2002@gmail.com
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                22 May 2020
                22 May 2020
                2020
                : 10
                : 8524
                Affiliations
                [1 ]ISNI 0000 0004 0639 2551, GRID grid.454209.e, Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, ; Keelung, Taiwan
                [2 ]Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, Taiwan
                [3 ]GRID grid.145695.a, Graduate Institute of Early Intervention, College of Medicine, Chang Gung University, ; Taoyuan, Taiwan
                [4 ]GRID grid.145695.a, School of Medicine, College of Medicine, Chang Gung University, ; Taoyuan, Taiwan
                [5 ]ISNI 0000 0004 0639 2551, GRID grid.454209.e, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, ; Keelung, Taiwan
                Author information
                http://orcid.org/0000-0002-2132-5256
                Article
                65335
                10.1038/s41598-020-65335-z
                7244586
                32444630
                f2e970b6-508f-4800-b1d6-4a061381b790
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 29 October 2019
                : 1 May 2020
                Funding
                Funded by: Chang Gung Medical Research Council under Contract No. CMRPG2H0011
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                sleep disorders,stroke
                Uncategorized
                sleep disorders, stroke

                Comments

                Comment on this article